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ABSTRACT 
Background: Current cervical dystonia (CD) incidence estimates are based 
on small numbers in relatively ethnically homogenous populations. 
Frequency and consequences of delayed CD diagnosis is poorly 
characterized. 
Objectives: To determine CD incidence and characterize CD diagnostic 
delay within a large, multiethnic integrated health maintenance organization.
Methods: We identified incident CD cases using electronic medical records 
and multistage screening of more than 3 million Kaiser Permanente Northern
California members during January 1, 2003–December 31, 2007. Final 
diagnosis was made by movement disorders specialist consensus. Diagnostic
delay was measured by questionnaire and health utilization data. Incidence 
rates were estimated assuming a Poisson distribution of cases and directly 
standardized to the 2000 United States census. Multivariate logistic 
regression models were employed to assess diagnoses and behaviors 
preceding CD compared to matched controls, adjusting for age, sex and 
membership duration. 
Results: CD incidence was 1.18/100,000 person-years (95% confidence 
interval [CI] 0.35, 2.0; women: 1.81, men: 0.52) based on 200 cases over 
15.4 million person-years. Incidence increased with age. Half of the CD 
patients interviewed reported diagnostic delay. Diagnoses more common in 
CD patients before index date included essential tremor (odds ratio [OR] 
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68.1, 95% CI 28.2, 164.5), cervical disc disease (OR 3.83, 95% CI 2.8, 5.2), 
neck sprain/strain (OR 2.77, 95% CI 1.99, 3.62), anxiety (OR 2.24, 95% CI 
1.63, 3.11) and depression (OR 1.94, 95% CI 1.4, 2.68).
Conclusions: CD incidence is greater in women and increases with age. 
Diagnostic delay is common and associated with adverse effects. 
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INTRODUCTION
Cervical dystonia (CD) is among the most common forms of focal dystonia in 
the neurology clinic.1-9 However, the true frequency of CD is not 
established.10, 11 Most estimates of CD prevalence are based on referral clinic 
populations.2-5, 7, 12-14 There are many advantages to studying population 
incidence, including the minimization of bias. Previous studies estimating CD 
incidence are based on small numbers of cases in homogenous populations, 
or rely on decades-old data that may now poorly represent increased 
awareness of dystonia among medical providers.15-17 The aims of this study 
were to determine the incidence of CD in a large, ethnically diverse 
population, identify the characteristics associated with a delayed diagnosis 
of CD, and delineate possible risk factors for developing CD.
METHODS
Study Population and Data Extraction 
Kaiser Permanente Northern California (KPNC) is an integrated healthcare 
system with over 3 million members that serves a diverse population across 
14 Northern Californian counties. Based on data from the 2003 California 
Health Interview Survey, Kaiser Permanente member demographics are 
similar to the non-Kaiser Permanente population.18 
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Cases and controls were ascertained through a review of the 
comprehensive clinical and administrative databases of KPNC. The 
multistage case identification process used by this study is detailed in Figure
1 and is based on our preliminary work15. 
Case Selection
Incident cases of CD were identified through a three-stage case identification
procedure. First, inpatient and outpatient visits and pharmacy records for all 
KPNC and non-KPNC services were screened for specific diagnostic codes and
write-in diagnoses for primary dystonia. Second, for all individuals with a CD 
diagnosis, a complete chronological list of all health service utilizations from 
the beginning of KPNC membership was generated for each individual. Each 
individual’s list was reviewed by one or more movement disorders specialists
to classify individuals as likely or unlikely to have cervical dystonia. Third, 
individuals judged likely to have cervical dystonia underwent a more 
extensive review by a movement disorders expert, including when possible a
neurological examination in person or via review of a standardized videotape
data collection by a trained research assistant during a home visit. Research 
diagnostic criteria appropriate to epidemiologic studies were developed by 
an expert panel convened by the Dystonia Medical Research Foundation 
(including CMT, SB, CC) and operationalized for use in KPNC. A final diagnosis
of cervical dystonia required: a) Diagnosis by a neurologist; b) No consistent 
change in neurologist’s diagnosis after index date; c) No antecedent 
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neuroleptic use; d) No identifiable associated medical or neurologic disorder 
known to include dystonia. Individuals were excluded if their dystonia was 
diagnosed prior to January 1, 2003 (i.e. prevalent cases) or after December 
31, 2007, or if they were not members of the KPNC system at the time of CD 
diagnosis. 
Medical records review, videotaped exam review and clinical 
examinations, conducted by movement disorders experts in subsets, 
included characterization of the abnormal posture, the presence or absence 
of superimposed movements, presence or absence of geste antagoniste, 
presence or absence of associated features, type of therapy and response to 
therapy as well as absence of another cause for the movement abnormality. 
In these validation subsets, agreement between utilization-defined 
cervical dystonia and medical record review was 88%, and between 
utilization defined CD and examination was 96%.  
Control Selection
Two control populations were assembled. For analyses based on the 
electronic medical record, 
control subjects were identified in order to determine the relative risk of 
clinical diagnoses preceding a diagnosis of CD. Ten controls were selected at 
random from the entire KPNC member base and matched to each case on 
birth year, sex, membership length, facility, and zip code (as a proxy for 
socioeconomic status). Electronic medical record (EMR) information was then
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pulled from the KPNC databases. For analyses based on interview data, 
control subjects were selected at random from the KPNC member base and 
matched one-to-one to enrolled cases based on birth year, sex and 
membership length. If a control did not complete the entire interview, 
another matched control was selected for the participating case.
Data Acquisition
Data were acquired from review of the EMR, health services utilization 
reports and mailed questionnaire. Information regarding incidence and 
antecedent clinical diagnoses was obtained from the EMR. The patient 
questionnaire provided detailed information on the frequency, character and 
impact of diagnostic error in persons with CD, as well as data regarding 
family history and demographics. 
Standard protocol approvals, registrations, and patient consents
This study was conducted with approval from the KPNC Institutional Review 
Board. Informed consent was obtained from each participant. 
Statistical Analysis
All statistical analyses were conducted using the SAS/STAT statistical 
software package, version 9.1 (SAS Institute Inc). Average annual incidence 
was calculated overall, and for sex-, race/ethnicity- and age-specific groups.19
Incidence rates and confidence intervals were estimated assuming a Poisson 
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distribution of cases within the Kaiser Permanente population. Direct 
standardization of rates for age, race/ethnicity and sex used the 2000 U.S. 
census population.  Incidence rates were presented per 100,000 person-
years.  
Behaviors and antecedent diagnoses were compared between CD 
cases and their interviewed controls (1:1) or EMR-control (1:10). Adjusted 
odds ratios (ORs) and 95% confidence intervals were calculated adjusting for
birth year, sex, membership length, facility, and zip code (as a proxy for 
socioeconomic status).
RESULTS
Cervical Dystonia Incidence and Subject Demographics 
Two hundred cases of incident primary cervical dystonia were identified over
15,489,433 person-years of observation. Incidence standardized to the US 
2000 Census population was 1.18 per 100,000 person-years (95% C.I.: 0.35, 
2.0). The age-, sex-, and race/ethnicity-specific rates are summarized in 
Table 1. CD incidence was significantly greater in women and Caucasians. 
The difference between mean age at incident diagnosis between men and 
women approached significance (men = 47 years, 95% C.I.: 42.29, 51.85; 
women = 54 years, 95% C.I.: 51.61, 56.43). Incidence appeared to increase 
with age through the 7th decade. 
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Cervical Dystonia Diagnostic Delay 
Of 200 CD cases, we had permission to contact and approach 114 cases. A 
total of 80 cases agreed to respond to questionnaires concerning risk factors,
diagnosis and treatment (70%); of those, a total of 58 cases (51%) 
responded to the survey addressing details of diagnosis. Diagnosis of CD was
delayed a median of 730 days after the onset of self-reported symptoms; a 
median of 3 physician visits occurred before the diagnosis was made. 
Characteristics of diagnostic delay derived from the patient questionnaire 
are outlined in Table 2. Fifty percent of patients reported unpleasant or 
harmful effects due to this delay. Sixty-six percent of those surveyed 
reported receiving treatment for an incorrect diagnosis prior to being 
diagnosed with CD. The most common treatments included muscle 
relaxants, physical therapy, anti-inflammatories, acupuncture, 
antidepressants, and trigger point injections. A quarter of those who received
treatment prior to CD diagnosis reported unpleasant or harmful side effects 
from those treatments. Following CD diagnosis, 83% of patients received 
botulinum toxin injections; of these, 89% reported that botulinum toxin 
injections were helpful.  The features associated with diagnostic delay are 
summarized in Table 3.
Medical Conditions Preceding Cervical Dystonia Diagnosis 
Patients ultimately diagnosed with cervical dystonia were more likely to be 
given certain diagnoses compared with controls. These diagnoses included 
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essential tremor (OR 68.1, 95% C.I. 28.2, 164.5), cervical disc disease (OR 
3.8, 95% C.I. 2.83, 5.17), neck sprain/strain (OR 2.68, 95% C.I. 1.99, 3.62), 
anxiety (OR 2.24, 95% C.I. 1.63, 3.11) and depression (OR 1.94, 95% C.I. 1.4,
2.68). Patients with CD were significantly more likely to have a diagnosis of 
neck trauma or pathology three and five years preceding the index date 
compared with controls (p=0.000 and p=0.002, respectively). Three years 
prior to diagnosis, patients with CD were significantly more likely than 
controls to be diagnosed with tremor, essential tremor, depression and 
anxiety (p < 0.001 for each), but not migraine (p=0.577). 
DISCUSSION 
In this study of cervical dystonia in patients within the Kaiser Permanente 
Northern California system, we found an estimated CD incidence of 
1.18/100,000 p-y based on 200 cases over 15.4 million p-y. This study 
incorporates the largest, most ethnically diverse cohort of incident cases of 
CD to date. Our estimated incidence of 1.18 per 100,000 person-years is 
similar to the preliminary incidence estimate we previously published for the 
years 1997-1999 (1.07 per 100,000 person-years).15 This current report is 
based on three times as many incident cases of CD, over twice as many 
person-years of observation, compared with our prior estimate. Due to the 
larger sample size, we are now able to evaluate differences among 
subgroups with more confidence and precision.   
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We found that the incidence of CD differs by sex. The incidence of CD 
was 3.5 times greater for women than for men. This strengthens our 
previous finding that the minimum estimated incidence of CD was 2.5 times 
greater for women.15 The majority of prior studies estimated CD prevalence, 
not incidence; these studies found sex prevalence ratios (female:male) 
ranging from 1.1-3.6:1.4, 7, 16, 20 However, unlike our study, these data were 
mostly derived from homogenous populations or from a small number of 
centers20. While the incidence of CD is higher for women, the age of CD onset
may be later for women than for men. The sex difference observed in our 
study may have several explanations. One possibility is rooted in genetics. 
While most cases of CD have no known cause, family history of dystonia 
remains an important risk factor.21 There are genetic links for many forms of 
dystonia, but these are not usually inherited on sex chromosomes.22 
However, our observation that the incidence of CD differs by race also raises 
the possibility of genetic contributions. Currently identified CD-related 
genetic mutations and variants are not sufficient to explain the observed sex
difference, though variable penetrance, epigenetic modification of gene 
expression, or gene-environment interactions may play a role. Differences in 
sex hormones are another possible explanation for this sex discrepancy. 
Rodent studies suggest that estrogen may protect the nigrostriatal 
dopaminergic system from damage through enhancing dopamine synthesis, 
increasing dopamine receptor sensitivity, and stimulating plasticity in this 
circuit.23-26 The decrease in estrogen during the peri- and post-menopausal 
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periods may be a driver of the observed increase in CD incidence for women 
later in life as compared to men.4, 7, 13 Sex differences may also result from 
differences in health-seeking behaviors or medical provider diagnostic bias. 
These could affect both the overall sex-specific incidence rates as well as 
apparent differences in age distribution. Lastly, these observations may also 
be due to exogenous risk factors, such as occupation. Additional study of 
genetic, molecular and environmental factors is necessary to better 
understand the relationship of sex to the development of CD.
Diagnostic delay is an important barrier to appropriate treatment for 
patients with dystonia, but few studies have characterized the magnitude of 
this obstacle. Our study suggests a greater percentage of misdiagnosis than 
prior studies, with 50% of patients endorsing harmful effects due to the 
delay.3, 27, 28 The consequences of diagnostic delay can be severe and include 
unnecessary healthcare costs, such as inappropriate testing and treatment. 
There are many reasons for CD delayed diagnosis, including mild or slowly 
progressive symptoms, fluctuation of symptoms not seen during a physician 
visit, focus by the physician on managing pain rather than the underlying 
cause of pain, and misdiagnosis as a psychogenic illness28, 29. Even in 
healthcare systems with equal access to care, such as KPNC, delayed 
diagnosis remains an important barrier. Given the significant improvement in
health-related quality of life in patients who receive botulinum toxin therapy 
for dystonia, it is imperative that physicians maintain a high level of 
suspicion for CD when examining a patient with neck muscle spasm.30, 31 
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Possible interventions to mitigate diagnostic delay include more robust 
education on diagnosing dystonia in medical school or through continued 
medical education courses.
Participants in this study were given multiple diagnoses preceding the 
diagnosis of CD. These alternate diagnoses may reflect comorbid conditions, 
diagnostic errors or etiologic factors.  For example, depression and anxiety 
could represent a misattribution of CD symptoms to a psychogenic cause, or 
may reflect the prominent mood disorders that can accompany a disabling 
neurological disease.28, 32 Potential triggers of CD in the literature include 
peripheral trauma, such as neck sprain or whiplash.21, 33-35 We found that 
patients diagnosed with CD were significantly more likely to be diagnosed 
with cervical disc disease or neck trauma preceding CD diagnosis compared 
with controls. A relationship between peripheral trauma and development of 
CD has been previously observed,35-37 such as in one case-control study, 
where 16 of 95 respondents reported a history of injury within four weeks of 
CD development.38 The pathophysiology of a peripherally – rather than 
centrally – mediated association remains unclear, and there continues to be 
debate regarding its existence.39 One possibility is a gene-environment 
interaction, where the peripheral trauma incites development of CD in 
someone with a genetic predisposition.40, 41 Aberrant peripheral inputs – such 
as from trauma – may provoke reorganization of neuronal circuitry more 
centrally.41, 42 There is suggestion that patients with dystonia have aberrant 
synaptic plasticity mediated by acetylcholine resulting in altered basal 
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ganglia networks.43 It is also possible that pain secondary to CD resulted in 
neck imaging that revealed cervical disc disease, which is common in the 
general population, and so this radiographic finding may be present but not 
contributory. Overall, the relationship between peripheral trauma and 
dystonia remains a challenging topic to study due to recall bias, and cause-
effect bias -- for example, unrecognized dystonia may result in injury, rather 
than the converse. A larger prospective study is warranted to better 
elucidate this potential association.
This investigation includes several strengths. We chose to minimize 
survival bias and differences in diagnostic practices by studying incident 
cases of CD during a specified five-year period rather than all prevalent CD 
cases. Our strict case definition and physician review of all suspected cases 
minimized the false-positive rate. In addition to its large size, there are many
advantages to studying CD in the KPNC population. All Kaiser Permanente 
members receive essentially equal access to health care and membership is 
precisely enumerated. Members benefit from equal access to expert care, 
including movement disorders specialists. The multiethnic KPNC cohort is 
demographically similar to the non-Kaiser Permanente population,18 
maximizing the generalizability of our findings. Centralized data collection 
within the Division of Research that spans across the Kaiser Permanente 
organization is another strength. 
This study has several limitations. We did not conduct population-wide 
examinations, so individuals never diagnosed are not included in our study. 
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This may result in an underestimation of CD incidence. The sample sizes for 
racial groups other than Caucasian were small and the categories were 
broad – for example, the classification of Asian within KPNC includes persons 
from multiple regions including the Indian subcontinent and the Pacific 
Islands – limiting our conclusions on racial differences. Lastly, our 
questionnaire characterizing diagnostic delay, mailed to the 114 of the 200 
CD cases we had permission to contact, was only answered by 58 cases. This
is a potential source of bias as there is a possibility of over- or 
underestimating the burden of delay.  
In conclusion, cervical dystonia is a disease with a female and 
Caucasian preponderance, with an incidence that increases with age. 
Despite increased awareness of this common movement disorder, there 
remain significant delays with diagnosis and treatment for patients with CD. 
Quality of life can greatly improve with simple therapies. Education of 
primary care physicians and general neurologists on recognition of CD, and 
screening tools with increased sensitivity and specificity, are needed to 
assist with making an accurate and timely diagnosis in this vulnerable 
patient population. 
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Figure 1. Case identification process for patients with cervical dystonia (CD) 
obtained from a multiethnic membership of a health maintenance 
organization in Northern California. 
Figure 2. Incidence of cervical dystonia by decade standardized to the US 
population during the year 2000. 
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